NOR-1 distinguishes acinic cell carcinoma from its mimics on fine-needle aspiration biopsy specimens.


Journal

Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547

Informations de publication

Date de publication:
08 2020
Historique:
received: 09 04 2020
accepted: 03 05 2020
pubmed: 18 5 2020
medline: 18 2 2021
entrez: 17 5 2020
Statut: ppublish

Résumé

Acinic cell carcinoma of the salivary gland (ACC-SG) is characterized by a recurrent chromosomal rearrangement (t(4; 9)(q13; q31)) that upregulates the transcription factor NR4A3. Studies conducted on formalin-fixed paraffin-embedded (FFPE) tissue have found that nuclear expression of a monoclonal antibody NR4A3 (NOR-1) is a sensitive and specific diagnostic marker for ACC-SG. The aims of this study were to evaluate the performance of the NOR-1 antibody and to compare its utility in separating ACC-SG from its mimics on cytology cell block specimens. Cell blocks were obtained from 70 fine-needle aspiration specimens from multiple institutional archives over a 7-year period (2013-2019). These included 10 cases of conventional low-grade ACC-SG, 1 case of dedifferentiated high-grade ACC-SG, and 59 cases of non-ACC-SG. An automated immunohistochemistry system (Bond-III, Leica) was used for the detection of NR4A3, using the commercially available antibody NOR-1 (sc-393902 [H-7], Santa Cruz Biotechnology Inc.). Optimization of the antibody on the cell blocks was successfully completed by increasing the titer from 1:100 (suggested titer for FFPE specimens) to 1:30. Distinct nuclear reactivity was observed in all 11 cases of ACC-SG (10 of 11 with 3+ diffuse nuclear positivity and 1 case with 2+ focal reactivity). Expression of NR4A3 was absent in all non-ACC-SG cases in the cell blocks. Application of the NOR-1 immunohistochemical staining in fine-needle aspirates of salivary gland tumors for which ACC-SG is a diagnostic consideration successfully distinguishes ACC-SG from its cytologic mimics and provides an early opportunity for oncologic intervention.

Identifiants

pubmed: 32416209
pii: S0046-8177(20)30088-5
doi: 10.1016/j.humpath.2020.05.001
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Biomarkers, Tumor 0
DNA-Binding Proteins 0
NR4A3 protein, human 0
Receptors, Steroid 0
Receptors, Thyroid Hormone 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-6

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Luan Nguyen (L)

Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. Electronic address: luan.nguyen2@cshs.org.

Shefali Chopra (S)

University of Southern California, Los Angeles, CA, 90007, USA.

Derek B Laskar (DB)

University of California Los Angeles, Los Angeles, CA, 90095, USA.

Jianyu Rao (J)

University of California Los Angeles, Los Angeles, CA, 90095, USA.

David Lieu (D)

FNA Medical Group, Alhambra, CA, 91801, USA.

Fai Chung (F)

Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Evelyn D Kim (ED)

Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Mariza de Peralta-Venturina (M)

Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Shikha Bose (S)

Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Bonnie Balzer (B)

Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH